Other Events ·
Galmed Pharmaceuticals terminated its License Agreement with Yissum Research Development Company effective July 31, 2026
GLMDGalmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals terminated its License Agreement with Yissum Research Development Company effective July 31, 2026. The decision follows a notice delivered on July 21, 2026, to discontinue funding licensed patents and cease all related activities. Consequently, rights to the technology revert to Yissum, and patent expense obligations end. This strategic move aims to consolidate operations, reduce costs, and focus resources on commercializing Colospan and developing Aramchol. Galmed Pharmaceuticals Ltd. operates in the biopharmaceutical industry, focusing on drug development and commercialization.